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Abstract: Malignant gliomas are invasive tumors with the potential to progress through current 
available therapies. These tumors are characterized by a number of abnormalities in molecular 
signaling that play roles in tumorigenesis, spread, and survival. These pathways are being actively 
investigated in both the pre-clinical and clinical settings as potential targets in the treatment of 
malignant gliomas. We will review many of the therapies that target the cancer cell, including 
the epidermal growth factor receptor, mammalian target of rapamycin, histone deacetylase, and 
farnesyl transferase. In addition, we will discuss strategies that target the extracellular matrix 
in which these cells reside as well as angiogenesis, a process emerging as central to tumor 
development and growth. Finally, we will briefly touch on the role of neural stem cells as both 
potential targets as well as delivery vectors for other therapies. Interdependence between these 
varied pathways, both in maintaining health and in causing disease, is clear. Thus, attempts to 
easily classify some targeted therapies are problematic.
Keywords: glioma, EGFR, mTOR, HDAC, Ras, angiogenesis
Introduction
Like all cancers, malignant gliomas are characterized by a wide number of genetic 
and epigenetic abnormalities that account for their properties: unregulated growth, 
invasion, and resistance to apoptosis. These include but are not limited to gene mutation, 
amplification, rearrangement and loss as well as promoter methylation and other 
mechanisms controlling gene expression. Furthermore, as these tumors develop and 
spread within a complex extracellular matrix (ECM), therapies that target this milieu are 
also under investigation. Finally, angiogenesis, a critical component of the neoplastic 
process, is emerging as a powerful area for targeted therapy of malignant gliomas.
As more is learned of the mechanisms underlying both malignant transformation 
and tumor–host relationships, new anti-cancer treatments are emerging. Many of 
these newer therapies target components of specific pathways that contribute to the 
malignant phenotype. These include various signal transduction pathways, those 
involved in angiogenesis, and still others that regulate the ECM. Collectively, these 
agents have come to be known as “targeted therapies.” The distinction is useful in that 
it distinguishes them from other cancer therapies, for example, covalent DNA-binding 
agents, whose mechanisms of action may be viewed as less specific. However, it should 
be noted that new agents targeting diverse aspects important in tumorigenesis such as 
the nucleosome and transcriptome as well as hormones and their receptors continue 
to emerge and may also prove valuable in anti-cancer therapy.OncoTargets and Therapy 2009:2 116
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Malignant gliomas are a heterogeneous group of 
tumors arising from either macroglial cells – astrocytes 
and oligodendroglia – or more likely their precursors. They 
infiltrate brain parenchyma thus existing within the cells and 
ECM of the normal central nervous system (CNS). The term 
‘malignant glioma’ is not recognized under the World Health 
Organization (WHO) tumor classification scheme.1 In clinical 
practice, however, the term is commonly used to distinguish 
between gliomas of relatively lower and higher histologic 
grades. In this review of our clinical experience with these 
tumors to date, some studies report findings based upon 
strict histologic criteria while others describe the experience 
with a variety of tumor types subsumed under the category 
‘malignant glioma.’
As more is learned of the molecular phenotypes of these 
heterogeneous neoplasms, our methods for classifying them 
are likely to change. Indeed, the rationale for the develop-
ment of targeted therapies depends upon our ability to define 
molecular characteristics that will predict responses to 
specific interventions. The tumors discussed in this review, 
their WHO classification, and select details regarding their 
molecular phenotypes are outlined in Table 1.
Some non-CNS tumors have proven to be quite sensitive 
to specific targeted therapies when used as single agents. 
Malignant gliomas have proven largely resistant to this 
approach. The reasons underlying our experience to date 
are complex but may relate to the molecular heterogene-
ity of malignant gliomas as well as redundancy in aberrant 
signaling pathways active in these complex tumors. Finally, 
their origin and residence within the CNS, a tissue that tightly 
regulates its intra- and extracellular milieu, may explain, in 
part, the modest results observed with targeted therapies to 
date. New compounds are under development and existing 
ones are now being used in combinations, both with one 
another and with other therapeutic modalities including 
conventional chemotherapy and radiotherapy.
Epidermal growth factor receptor
Our discussion begins with epidermal growth factor receptor 
(EGFR), one of the most studied potential targets in gliomas. 
EGFR is a human EGF receptor (HER)-family tyrosine 
kinase. It consists of an extracellular ligand-binding domain, 
a single transmembrane domain, and an intracellular tyro-
sine kinase domain. EGFR dysregulation can occur at many 
levels in malignant gliomas. Often more than one alteration 
is present in the same tumor. This is especially true with 
glioblastoma multiforme (GBM), the most common and 
aggressive of these tumors. As shown in Table 1, GBM are 
classified as either primary, arising de novo; or secondary, 
arising as a consequence of progression from a tumor of 
lower grade.1 Structural and/or functional abnormalities in 
the EGFR gene and protein expression differ substantially 
between these two subsets. For example, EGFR gene ampli-
fication is seen in 40%–60% of primary GBM with increased 
protein expression in 50%–60%.2 This phenomenon is sel-
dom encountered in secondary GBM. Similarly, EGFR gene 
mutations are common in primary GBM, encountered in 
40%–50%, but rare in secondary cases. The majority of the 
mutations are truncations. Five are recognized and classified 
as variants I–V (vI–vV). Of these, the constitutively active, 
ligand-independent vIII mutation is most common.3
The EGFRvIII mutation has been reported in 27% to 
50% of GBM patients.3–5 It is found only in tumors with 
EGFR overexpression or amplification. The presence 
of EGFR overexpression and amplification is closely 
correlated.6 Similar alterations in EGFR gene structure 
and protein expression are uncommon in both lower grade 
astrocytomas and oligodendroglioma.7 EGFRvIII is formed 
by an in-frame 268 amino acid deletion of exons 2 to 7 in the 
extracellular domain of the receptor. This creates a unique 
epitope which can serve as a target for therapies discussed 
further on. EGFRvIII does not bind to the EGFR ligands. 
It remains surface-bound and does not internalize. There is 
some evidence demonstrating that EGFR amplification and 
EGFRvIII overexpression confer a poor prognosis for overall 
survival.6 Total expression levels of EGFR do not appear to 
have prognostic significance.8
Upon binding one of several potential ligands (EGF, 
transforming growth factor-α [TGFα], and others), EGFR 
Table 1 WHO classification of tumors subsumed under the category 
“Malignant glioma”
Tumor  
type
WHO  
grade
Aberrant  
pathways
Anaplastic astrocytoma iii p53, MDM2, rb
Anaplastic 
oligodendroglioma
iii p53, PTeN, rb,
Anaplastic 
oligoastrocytoma
iii p53, PTeN, rb
Glioblastoma 
multiforme
iv eGFr, PTeN, p16,   veGF,
MDM2
p53, PDGFr, p16, rb, veGF   – Primary (de novo)
  – Secondary
Abbreviations: eGFr, epidermal growth factor receptor; PTeN, phosphatase and 
tensin homologue deleted on chromosome 10; PDGFr, platelet-derived growth factor 
receptor; rb, retinoblastoma;   veGF, vascular endothelial growth factor; MDM2, murine 
double minute 2;   wHO, world Health Organization.OncoTargets and Therapy 2009:2 117
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homo- or heterodimerizes with other HER-family receptors 
leading to autophosphorylation of the tyrosine residues on 
its intracellular domain.9 This leads to downstream activation 
of several pathways important in the development of the 
malignant phenotype, outlined in Figure 1. As more is 
learned about these downstream pathways, new areas for 
the development of targeted therapies are emerging. We 
will discuss agents that directly target EGFR first and then 
proceed to its varied potential downstream targets in the 
sections that follow.
eGFr small molecule inhibitors
Several tyrosine kinase inhibitors (TKIs) that downregulate 
EGFR-mediated signaling by blocking its intracellular ATP 
domain have been developed and tested as therapeutic 
agents against a wide variety of cancers, including malignant 
glioma. Two of the most studied agents – erlotinib (OSI-774, 
Tarceva®; Genentech, San Francisco, CA) and gefitinib 
(ZD1839, Iressa®; AstraZeneca, Washington, DC) – have 
been employed in both phase I and II clinical trials involving 
malignant gliomas of varying grades and histologies. These 
are summarized in Table 2. Although neither agent met 
the predetermined efficacy endpoints in any study, striking 
and durable responses to treatments were seen in a subset 
of patients. An example of such a response is shown in 
Figure 2. Because of these remarkable responses in tumors 
largely refractory to all therapy, attempts have been made 
to understand the molecular mechanisms that underlie the 
success or failure of these agents in order to improve their 
therapeutic impact. There are many potential causes for both 
the success and failure of single-agent TKIs as antiglioma 
therapy. In order to understand these influences we must 
move downstream of EFGR to some of the pathways 
influenced by EGFR activation.
The first pathway which we will discuss will be the 
phosphatidylinositol-3-kinase (PI3K)/Akt pathway. 
Following EGFR activation, PI3K catalyzes the conversion 
of phosphatidylinositol-4,5-bisphosphate (PIP2) to 
(TKIs)
(FTIs)
(mTORIs)
PI3K
PIP2
EGFR
apoptosis
PIP3
Akt
S6k Translation
mTOR
p70s6k
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MAPK
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Figure 1 Simplified diagram of the two major pathways affected by EGFR-mediated signaling in malignant glioma cells. The PI3 kinase pathway is shown on the right and 
the ras/Map kinase pathway on the left. Following eGFr activation, a series of sequential phosphorylation events result in cell proliferation and survival through increased 
transcription and translation of key proteins while inhibiting pro-apoptotic pathways. Agents that target key points in the pathway that are discussed in the text are shown in 
parentheses at their respective sites of action.
Abbreviation: eGFr, epidermal growth factor receptor; mTOr, mammalian target of rapamycin; mTOri, mTOr inhibitor; TKi, tyrosine kinase inhibitor; FTi, farnesyl trans-
ferase inhibitor; HDACi, histone deacetylase inhibitor; PTeN, phosphatase and tensin homologue deleted on chromosome 10; MAPK, mitogen-activated protein kinase; Pi3K, 
phosphoinositide 3-kinase; PiP2, phosphatidylinositol 4,5-bisphosphate; PiP3, phosphatidylinositol (3,4,5)-triphosphate.OncoTargets and Therapy 2009:2 118
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phosphatidylinositol-3,4,5-triphosphate (PIP3), as shown 
on the right side in Figure 1. PI3K has been shown in other 
cancers to be activated by the Ras pathway, which will be 
discussed later.10 Subsequent phosphorylation of the serine/
threonine kinase, Akt, promotes cell growth, and proliferation 
through the mammalian target of rapamycin (mTOR) 
while simultaneously inhibiting apoptosis.11 Additional 
perturbations at several points in this pathway could render 
the single-agent TKIs discussed above inactive. For example, 
as shown in Figures 1 and 3, PIP3 is dephosphorylated back 
to PIP2 by the tumor suppressor gene, phosphatase and 
tensin homologue deleted on chromosome 10 (PTEN). PTEN 
function is affected by gene deletion and/or mutation in the 
majority of GBM.12 Again, this is more commonly seen in 
primary than either secondary GBM or malignant gliomas 
of lower grade.12
Two retrospective studies using selected samples from 
two of the clinical trials discussed above where tumor 
responses were observed, attempted to determine the pre-
dictive value of EGFR status (wild-type or EGFRvIII) in 
combination with PTEN activity to TKI response. Each 
study used different methods to investigate this hypothesis, 
reaching partially contradictive conclusions. In one report, 
only those tumors expressing EGFRvIII in the presence of 
intact PTEN were responsive to inhibition by these TKIs.13 
In the other, only tumors expressing wild-type EGFR (not 
Table 2 epidermal growth factor receptor tyrosine kinase inhibitor trials in adult malignant gliomas
Author Agent Phase N Histology Newly Dx vs Progression
de Groot et al121 erlotinib Carboplatin ii 44 GBM Progression
Brown et al122 erlotinib Temozolomide rT i/ii 97 GBM Newly Dx
Prados et al118 erlotinib Temozolomide i 83 GBM, AA, AO, AOA Progression
Haas-Kogan et al14 erlotinib Temozolomide i 41 GBM, AA, AO, GA, A, O Progression
Schwer et al124 Gefitinib SRS i 15 GBM, AA Progression
Franceshi et al120 Gefitinib ii 28 GBM, AA, AO Progression
rich et al125 Gefitinib ii 57 GBM Progression
reardon et al126 Gefitinib Sirolimus i 34 GBM, AA Progression
Prados et al127 Gefitinib Temozolomide i 28 GBM, AA, AOA, AO Progression
Preusser et al119 Erlotinib Gefitinib ii 21 GBM, AA, AOA Progression
Lassman et al117 Erlotinib Gefitinib i/ii 33 GBM, AA, AOA Progression
Doherty et al29 Erlotinib Gefitinib Sirolimus i 28 GBM, AG Progression
Mellinghoff et al13 Erlotinib Gefitinib Temozolomide 82 GBM, AO Progression
Abbreviations: GBM, glioblastoma multiforme (gliosarcoma subjects are also included under this heading);   AA, anaplastic astrocytoma;   AO, anaplastic oligodendroglioma;   AOA, anaplastic 
oligoastrocytoma;   A, astrocytoma; Dx, diagnosis; O, oligodendroglioma; GA, gemistocytic astrocytoma;   AG, anaplastic glioma (nonspecified); RT, radiation therapy; SRS, stereotactic 
radiosurgery.
Figure 2 Mri scans showing a typical prolonged response to single-agent erlotinib in a patient with progressive GBM. The image in the left panel is consistent with a partially 
necrotic enhancing mass and surrounding peri-tumoral edema. The image on the right, obtained 16 months after the initiation of erlotinib, reveals a decrease in the mass and 
associated edema. The patient was on high-dose dexamethasone treatment (to control cerebral edema) at the time of erlotinib treatment initiation and was off all dexametha-
sone at the time of the follow-up scan.
Abbreviations: GBM, glioblastoma multiforme; Mri, magnetic resonance imaging.OncoTargets and Therapy 2009:2 119
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tumor-expressing EGFRvIII) responded to therapy.14 In 
the latter study, PTEN activity was implied by studying 
activation of Akt, its downstream target. In this case, no 
tumor thought to lack PTEN activity responded to therapy 
with these agents. Based upon these observations, it would 
appear that functional PTEN is necessary (but perhaps not 
sufficient) for TKI activity in malignant glioma. Particulars 
surrounding EGFR status remain unclear, however. There 
are no reported mutations in the EGFR TKI-binding domain 
in gliomas that would render EGFR TKIs ineffective as have 
been demonstrated in other cancers.15
Additional, untested hypotheses that might explain 
these results also exist. For example, potentially oncogenic 
mutations in a PIK3CA gene encoding the p110α catalytic 
subunit of PI3K are well documented in GBM16 (see Figure 3). 
Activation by Ras binding to PIK3CA has been noted in 
other solid tumors.10 Furthermore, increased expression of 
the Akt modulator, PI3K-enhancer (PIKE-A), is also seen 
in gliomas.17,18 Activity at one or both of these sites could 
render TKIs unsuccessful, independent of EGFR and/or 
PTEN status. On the other hand, it does not appear that direct 
dysregulation or mutation of Akt plays a significant role in 
mediating this resistance. Of note, there has been only one 
report of mutation of the Akt1 isoform in a gliosarcoma.19 
Finally, alterations in the Ras/mitogen-activated protein 
kinase (MAPK) pathway (shown on the left in Figure 1 and 
discussed in detail below) might also influence susceptibility 
of malignant gliomas to inhibition by TKIs. In summary, 
given the complexity of the pathways involved and the many 
points at which important alterations can occur, it is not 
surprising that a straightforward predictive test for response 
to single-agent TKIs eludes us.
Anti-eGFr antibodies
Some of the same proteins integral to molecular signaling 
pathways may also serve as either tumor-enriched or – 
specific targets of antibodies. Monoclonal antibodies (mAb) 
are used with increasing frequency in cancer therapy. They 
have the advantage of high specificity for their targets, yet 
may exert their effects through several mechanisms. mAb 
receptor binding can result in either receptor activation or 
inhibition. Alternatively, mAb may cause a cell’s death via 
antibody-dependent cellular toxicity (ADCC). Furthermore, 
they may be used as carriers of toxins to enhance their 
Activated EGFR
PI3K
Akt
PIKE-A EXPRESSION
ACTIVATING PIK3CA MUTATIONS
Akt
DOWNSTREAM
EFFECTS
P
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PTEN
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Figure 3 Schematic diagram of the potential sites in the Pi3 kinase pathway where resistance to single-agent TKis directed against the eGFr might occur. 1) The phosphatase 
activity of the PTEN gene product is lost in the majority of GBM, favoring accumulation of the triphosphate form of phosphatylinositol, PIP3; 2) Activating mutations in the 
PiK3CA gene, controlling the catalytic subunit of Pi3K are well-documented, also favoring accumulation of PiP3; 3) in addition, increased expression of the phospho-AKT 
enhancer, PiKe-A, is found. These alterations may occur in isolation or in any combination in GBM.
Abbreviations: eGFr, epidermal growth factor receptor; GBM, glioblastoma multiforme; PTeN, phosphatase and tensin homologue deleted on chromosome 10; TKis, tyrosine 
kinase inhibitors.OncoTargets and Therapy 2009:2 120
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specificity and reduce toxicity. Targeted antibody therapy has 
been used successfully in breast cancer with the anti-HER2 
antibody trastuzumab (Herceptin®; Genentech) and in 
colorectal cancer with the anti-wtEGFR and anti-EGFRvIII 
antibody cetuximab (IMC-C225, Erbitux®; Bristol-Myers 
Squibb, New York, NY).
Evidence for mAb uptake in malignant gliomas following 
intravenous (IV) administration comes from several sources. 
Two studies using the EGFR-specific murine monoclonal 
antibody, MAb 425 (EMD55900; Merck and Co., Inc., 
Whitehouse Station, NJ), demonstrated binding in human 
brain tissue. These studies provided proof of concept but were 
not powered to evaluate efficacy.20,21 A phase I/II trial using 
the radiolabelled EGFR-specific humanized monoclonal 
antibody nimotuzumab (hR3, OSAG 101, Therolac®; 
Oncoscience AG, Wedel, Germany) also demonstrated 
some tumor uptake.22 EGFR antibodies have also been 
combined with radiotherapy with the antibody serving as 
a directed carrier. A small randomized study using MAb 
425 bound to iodine125 administered IV in patients with 
grade III and IV gliomas noted no benefit.23 Other trials 
using antibodies to target EGFR in gliomas are ongoing 
and include: IV cetuximab, in combination with radiation 
therapy (RT) and temozolomide,24 nimotuzumab either in 
combination with RT in diffuse pontine gliomas or alone at 
recurrence, as well as a phase III trial in GBM adding it to 
temozolomide after RT/temozolomide, and a large phase II 
trial of MAb 425 bound to I125.
The relatively large size of mAbs has raised concerns 
about their potential for use in the treatment of malignant 
glioma. The blood–brain barrier (BBB) is usually cited as the 
main concern as it may limit access of mAb, administered 
systemically, to their targets. It should be noted, however, 
that the blood–brain tumor barrier (BBTB) differs sig-
nificantly from the BBB. Furthermore, as discussed above, 
there is evidence for at least some delivery of mAb, admin-
istered systemically, to brain tumors. Thus, the failure of an 
antibody-directed therapy may or may not be due to issues of 
intra-tumoral mAb concentration. Nevertheless, this concern 
has led to a variety of techniques aimed at “circumventing” 
the BBB. Preclinical data include the use of cetuximab, either 
alone or in combination with boronated EGFRvIII-specific 
antibodies (L8A4) given intratumorally by convection-
enhanced delivery (CED) in rat glioma models.25 Thus far, 
one phase I clinical trial using intracavitary administration of 
radiolabelled nimotuzumab in the treatment of progressive 
GBM and AA has been published. Of the 11 patients 
enrolled, one with an AA demonstrated a sustained complete 
radiographic response (CR). The complications noted in the 
study include those associated with intracranial catheters as 
well as radiation necrosis.26
eGFr vaccines
Vaccines capable of producing both humoral (antibody 
mediated) and cell-mediated anti-brain tumor responses are 
an area of basic, translational, and clinical research. True 
for most cancers, the identification of brain tumor-specific 
antigens has proven challenging. In the case of malignant 
glioma, the EGFRvIII mutant has proven a highly specific 
target in those cases where it is expressed. An antigenic 
epitope on this mutant receptor stimulates highly specific 
humoral and cellular immune responses. This has been 
studied in both pre-clinical models and phase I and II studies 
in patients with recurrent malignant glioma.27,28 An immune 
attack in the CNS focused on a tumor-specific epitope raises 
concern for collateral damage. The relative immune privi-
lege of the CNS also makes one question the ability to raise 
an adequate immune response to the tumor target. To the 
surprise of many, this approach has proven to be safe and 
also appears effective for some patients.27 Based on these 
findings, a phase II clinical trial is ongoing in patients with 
newly diagnosed GBM.
mTOr inhibitors
As shown in Figure 1, the serine/threonine kinase, mTOR, lies 
downstream of Akt in the PI3K pathway. mTOR is involved 
in the regulation of cell growth, proliferation, motility, and 
survival. mTOR, in turn, activates another serine-threonine 
kinase, p70s6 kinase (p70s6K). p70s6K serves as a point 
of convergence for the Ras/MAPK/extracellular signal 
regulated kinase (ERK) pathway (see Figure 1). p70s6K 
in turn activates S6K which phosphorylates the ribosomal 
protein S6. Activated S6 upregulates translation. Of potential 
importance in glioma biology and therapy, the tuberous 
sclerosis complex 1 and 2 gene products (TSC1 and TSC2, 
respectively) inhibit S6K activation (Figure 4).30 TSC1 
and TSC2 mutations are involved in the development of 
subependymal giant cell astrocytomas, a low grade tumor 
found in patients with tuberous sclerosis. Although mutations 
of TSC 1 and 2 are not found in high-grade gliomas, loss 
of function of these proteins may prove to play a role in the 
development of a small percentage of high-grade gliomas 
as well, making them potential targets for directed thera-
pies. Loss of heterozygosity (LOH) for either the TSC1 or 
TSC2 locus was found in less than 10% of grade III and IV 
astrocytomas. No mutations of the intact allele were found. OncoTargets and Therapy 2009:2 121
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It is possible that LOH at these loci is merely an expression 
of the myriad genetic aberrancies in malignant gliomas. It is 
also possible that there may be transcriptional silencing of 
the gene. It has been recently demonstrated that TSC1 and 
TSC2 mRNA levels in GBM are decreased in comparison 
to normal brain or grade II astrocytomas.31 While there are a 
number of points in this pathway where modulation may be 
of benefit for the treatment of gliomas, we will limit our focus 
to mTOR inhibitors before proceeding to the RAS/MAPK 
pathway.
In malignant gliomas a number of mTOR inhibitors 
have been studied in the treatment of malignant glioma. 
These include: sirolimus (Rapamune®; Wyeth Pharma-
ceuticals, Madison, NJ) US Food and Drug Administra-
tion (FDA)-approved for the prophylaxis of solid organ 
transplant rejection and temsirolimus (CCI-779, Torisel®; 
Wyeth Pharmaceuticals) FDA-approved for use in renal 
cancer. Both everolimus (RAD001; Novartis Oncology, 
East Hanover, NJ) and deferolimus (AP23573; ARIAD/
Merck), still experimental, have all been evaluated in 
clinical trials alone or in combination with other therapies 
in gliomas.
Sirolimus has been evaluated in combination with the 
EGFR TKIs erlotinib or gefitinib in a retrospective case series 
of patients with recurrent malignant gliomas. The six-month 
progression-free survival (PFS-6) was encouraging and 
the majority of patients had either stable disease or partial 
response on radiographic imaging.29,32 A phase I trial using it 
in combination with gefitinib demonstrated tolerability and 
with over 40% of the patients demonstrating stable disease 
(SD) or partial response (PR), the results are promising.30 
There is currently one active phase I/II trial in gliomas 
using sirolimus as a single agent and two trials evaluating 
sirolimus in combination with erlotinib. The use of mTOR 
inhibitors in combination with EGFR-specific TKIs is ratio-
nal given the evidence, discussed above, for resistance to 
single agent EGFR-specific TKIs in the majority of those 
with GBM.
Temsirolimus, an ester analogue of sirolimus, was 
evaluated as a single agent in a phase II trial of recurrent 
GBM. No patients had radiographic response based on the 
criteria used.33 However, approximately a third of patients had 
a qualitative decrease in enhancement or mass effect while on 
a stable or decreased dose of steroids. Unfortunately PFS-6 
in these heavily pretreated patients was low. Correlative 
studies demonstrated potential to predict response prior to 
treatment by detecting elevated tumor levels of the down-
stream phosphorylated p70s kinase. In addition, early onset 
hyperlipidemia may have been predictive of a response.33 
Another phase II trial evaluating temsirolimus in recurrent 
primary GBM found radiographic stabilization with SD or PR 
but no prolonged survival.34 There are currently a number of 
ongoing clinical trials further evaluating temsirolimus alone 
or in combination with various agents including targeted 
therapies such as erlotinib, sorafenib (a multiple kinase 
inhibitor) (Nexavar®; Bayer, Pittsburgh, PA), the farnesyl 
transferase inhibitor (FTI) tipifarnib (R115777, Zarnestra®; 
Johnson and Johnson, Langhorne, PA), and the antiangio-
genic agent bevacizumab (Avastin®; Genentech) as well as 
the alkylating agent temozolomide for malignant gliomas.
Everolimus may, in addition to its mTOR activity, enhance 
the effects of radiotherapy.35 Thus, its further evaluation in 
gliomas is warranted. Furthermore, when everolimus was 
P725
3V.
6N
6
7UDQVODWLRQ
76&
76&
(5.
Figure 4 A schematic showing the convergence of the Pi3K pathway (through 
mTOr) and the ras/MAPK pathway (through erK) on p70s6K and its effect on 
translation. Note the inhibitory effect of TSC1 and 2, an area not fully explored in 
gliomagenesis.
Abbreviations: erK, extracellular signal regulated kinase; MAPK, mitogen-activated 
protein kinase; mTOr, mammalian target of rapamycin; TSC, tuberous sclerosis complex.OncoTargets and Therapy 2009:2 122
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used in combination with the EGFR/vascular endothelial 
growth factor receptor 2 (VEGFR2) TKI, AEE788 (Novartis) 
it demonstrated improved growth inhibition and median 
survival greater than with single agents in human glioma 
xenografts in mice.36 Studies evaluating its use as a single 
agent or in combination with temozolomide or with other tar-
geted agents including the multiple kinase inhibitor imatinib 
(Gleevec®; Novartis), gefitinib, AEE788, and bevacizumab 
are ongoing. There are no published clinical trial results to 
date using everolimus in any brain tumor setting.
rAS
The Ras/MAPK signal transduction pathway represents 
another key pathway mediated by EGFR (see Figure 1, left 
side). Ras, consists of a family of guanosine triphospha-
tases (GTPases): H-ras, K-ras, N-ras, activated when they 
move from the cytoplasm to a membrane bound state. This 
process is modulated in part by prenylation, the adding of 
farnesyl or geranylgeranyl to the carboxy-terminal cysteine 
residue of the proteins, and known respectively as farne-
sylation or geranylation 38 Unlike many other solid tumors, 
there are only rare activating mutations of Ras described in 
human GBMs.37,39 However, amplification of Ras is com-
monly seen in a variety of human gliomas, making it an apt 
therapeutic target.40 Furthermore, over-activation of EGFR 
in both its wild-type and mutant forms as well as over-
activation of platelet-derived growth factor (PDGF) may 
lead to over-activation of Ras.41,42 Upstream TKI activity is 
therefore likely adequate for upregulation of Ras.58 Ras, in 
turn activates the MAPK pathway as well as the PI3K/Akt 
pathway discussed earlier.
Farnesyl transferase inhibitors
Farnesyl transferase inhibitors (FTIs), although typically 
classified as targeted therapies, have potential effects on 
a broad range of proteins (∼300) which are controlled by 
farnesylation. This leads to the conjecture that FTIs may be 
of benefit in multiple subtypes of malignant gliomas. Their 
broad effects may be of benefit not only in the tumors with 
Ras pathway upregulation, the context in which they were 
developed, based on data from in vitro models.40,57
Tipifarnib is a FTI that has been used during and follow-
ing RT in phase I trials with malignant gliomas of varying 
grades, including GBMs and pediatric diffuse brain stem 
gliomas.43–45 Results of two phase II studies for progressive 
brain tumors have been published to date: one in adults with 
recurrent malignant gliomas, the other in children tumors of 
several types, including malignant gliomas.46,47 There was 
suggestion of some benefit in adults who were thought to 
have received adequate doses. Another recently published 
trial of tipifarnib did not demonstrate benefit when used prior 
to radiation.49 Lovastatin® (Merck), used primarily in the 
treatment of dyslipidemia, affects prenylation and has been 
evaluated as a single agent in a phase I/II trial of recurrent 
malignant glioma.48 The novel route of intranasal administra-
tion of perillyl alcohol for its FTI properties has been evalu-
ated in a phase I/II clinical trial.51 It is likely that FTIs such 
as tipifarnib, and agents with FTI effects such as lovastatin, 
will be investigated further in gliomas in combination with 
other agents, particularly those that target the PI3K pathway 
as these converge on p70s6K (see Figure 1).
Histone deacetylase inhibitors
Gene transcription is controlled, in part, by histone acetyla-
tion. Two enzymes, histone acetyl transferase and histone 
deacetlyase (HDAC), mediate this state and are in dynamic 
equilibrium in the cell. HDAC inhibitors (HDACI) are 
thought to mediate their anti-tumor effect by causing an 
accumulation of acetylated histones, leading to a relaxation 
of chromatin. This leads in turn to increased transcription.52 
HDACIs may facilitate preferential expression of tumor sup-
pressor genes, in part, by releasing epigenetically controlled 
gene silencing.52 HDACI may also affect the cytoskeleton 
in turn interfering with the mitotic process. Thus, the poten-
tial exists for HDACIs to influence the cancer cell at many 
levels.53
SAHA (suberoylanilide hydroxamic acid, vorinostat, 
Zolinza®; Merck), FDA-approved for cutaneous T-cell 
lymphoma, is being evaluated in clinical trials of multiple 
cancers, including malignant gliomas. Upregulation of 
pro-aptotic genes such as TNFα and downregulation of 
pro-growth and anti-apoptotic genes has been demonstrated 
in glioma cell lines treated with SAHA.54 It has also been 
demonstrated that SAHA can cross the BBB in mouse glioma 
xenografts.54 There are yet no published glioma trials using 
SAHA. However, there are a number of ongoing phase I 
and II clinical trials with this agent. The majority of these 
are using it in combination with nontargeted therapies such 
as temozolomide, carboplatin, as well as bevacizumab, 
isotretinoin (cis-retinoic acid, Accutane®; Roche, Nutley, NJ) 
the proteosome inhibitor bortezomib (Velcade®; Millennium 
Pharmaceuticals, Cambridge, MA).
The anticonvulsant valproic acid (Depakote®) has 
demonstrated HDACI activity preclinically in models 
of brain tumors as well as many other types of cancer.56 
A synergistic effect between valproic acid and RT has been OncoTargets and Therapy 2009:2 123
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shown as well.55 There is an ongoing trial adding valproic 
acid to the standard of care regimen of RT and temozolo-
mide in newly diagnosed GBM. Thus far, no clinical data 
have been published specifically regarding valproic acid’s 
HDAC inhibition. However, a limited number of patients in 
other clinical trials for brain tumors have had their seizures 
treated with valproic acid. There have been no retrospective 
evaluations of prior brain tumor trials to look for additive 
or synergistic effects in the patients taking valproic acid as 
well as the study agent.
Angiogenesis
The next therapeutic target we will discuss is angionesis, 
the process of new blood vessel growth in both normal 
as well as pathologic states. These investigations began 
with the hypothesis that both tumor growth and spread 
is angiogenesis-dependant. The first successful use of an 
angiogenesis inhibitor involved the cytokine, interferon-alpha 
(IFNα).60,61 Since then, the anti-angiogenic properties of 
many agents have been explored. Gliomas differ from many 
other solid tumors in that they seldom metastasize to other 
sites. However, some malignant gliomas are defined, in part, 
by endothelial proliferation. GBM demonstrates a greater 
degree of angiogenesis than most other tumors.63 It stands 
to reason that the inhibition of angiogenesis would become a 
focus of anti-glioma therapy, perhaps controlling the growth 
of the highest grade tumors and preventing the progression of 
tumors from lower to higher grades. Finally, anti-angiogenic 
strategies may also alter the vascular niche, which in turn 
may directly affect the neural stem cells which may be the 
progenitors of tumor cells.64
iFNα and β
The first anti-angiogenic agent studied in humans was 
IFNα.61 IFNα has been tested in a large phase III clinical trial 
in grade III or IV gliomas in combination with the nitrosurea, 
carmustine (BCNU) vs carmustine alone. There was no 
improvement in overall survival (OS) or time to progression 
(TTP).66 IFNα has also been evaluated in combination with a 
number of other agents including isotretinoin and tamoxifen 
without notable benefit.67,68 Interferon-β (IFNβ) has also been 
used, both alone and in combination with other agents in the 
treatment of newly diagnosed and recurrent gliomas. Results 
have been modest.65
Thalidomide and related compounds
Thalidomide is a therapeutic agent with a long history. 
Initially used as a sedative, it was found to be teratogenic, 
causing the maldevelopment of limbs in children born to 
mothers taking it while pregnant. It is thought that the anti-
angiogenic activity of thalidomide, only discovered many 
years later, was at least partially responsible for the birth 
defects.69 Thalidomide is thought to work through a number 
of mechanisms. One of the primary anti-angiogenic effects 
is deemed to be secondary to its inhibition of basic fibroblast 
growth factor (bFGF). A number of additional mechanisms 
may have both antiangiogenic as well as more broad anti-
tumor activity including: modulation of the expression of 
adhesion molecules, downregulation of TNF, as well as 
stimulation of CD8+ T-cell responses.69,70
A number of studies using thalidomide, either alone 
or in combination with cytotoxic chemotherapies have 
been completed in malignant gliomas both at recurrence as 
well as in the newly diagnosed setting. When compared to 
historical controls, thalidomide used in combination with the 
alkylating agent temozolomide in the newly diagnosed setting 
demonstrated benefit when compared to nitrosoureas.71 
When compared to temozolomide alone, the benefit is less 
apparent.71 When used for GBM at first diagnosis in combi-
nation with temozolomide and another agent with potential 
antiangiogenic properties, celecoxib there was no significant 
improvement in progression free survival.72
Lenalidomide (CC-5013, Revlimid®; Celgene), a 
thalidomide analogue used to treat multiple myeloma and 
myelodysplastic syndrome, has been used in the treatment of 
malignant gliomas. In preclinical studies, the anti-angiogenic 
effects of lenalinomide are more pronounced than those of 
thalidomide.77 Decreased VEGF secretion and decreased 
phosphorylated Akt have been found in cellular models of 
cancers treated with the agent.78 A phase I trial of single-
agent lenalidomide in recurrent primary brain tumors mostly 
GBMs, has been completed.79 It was found to be tolerable. It 
is currently being investigated either alone or in combination 
with other therapies in primary brain tumors in both phase I 
and phase I/II trials,
Anti-veGF antibodies
VEGF is a potent angiogenic cytokine. Several VEGF 
isoforms are recognized. They play variable roles in 
embryogenesis, neo-angiogenesis, and lymphatic channel 
formation.73 The interaction between isoform VEGF-A 
and its primary transmembrane receptor, VEGFR-2 is the 
predominant driving force for angiogenesis. The process, 
however, is more complicated. Interactions between the 
various VEGF subtypes and their respective receptors as well 
as other stimulatory molecules (ie, platelet derived growth OncoTargets and Therapy 2009:2 124
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factor) and their receptors, also influence this process. These 
pathways may be modulated by a number of other signals, 
including angiopoietin-1 (Ang1) and angiopoietin-2 (Ang2), 
molecules that are integral to the stabilization/destabilization 
of blood vessels.74
VEGF is produced by most (60%) human tumors. Its 
expression is upregulated in only some AAs, but in most 
GBMs.75 This is likely a necessary, but not alone sufficient, 
stimulus in driving the progression of secondary GBM from 
tumors of lower grade. For this reason, anti-VEGF therapies 
are under active investigation. Bevacizumab, a recombinant 
humanized monoclonal antibody directed against VEGF-A, 
is being evaluated both alone and in combination with other 
agents in the treatment of both newly diagnosed and recurrent 
malignant gliomas. Considerable interest has been generated 
in the remarkable radiographic responses, (reduced enhance-
ment and tumor-associated edema), seen following its use 
(see Figure 5). While encouraging, and often correlated with 
an improvement in symptoms, this effect has clouded attempts 
to determine the response rate in these tumors when compared 
to historical controls and is leading to new paradigms for 
determining both tumor response and its duration.76 Those 
agents that either have been or are now being used in com-
bination with bevacizumab include both temozolomide and 
irinotecan (CPT-11, Camptosar®, Pfizer), a topoisomerase-I 
inhibitor, at recurrence or at initial diagnosis of high grade 
gliomas.76,80–84 The results of these trials are promising in this 
group of relatively refractory patients. Both 6PFS and OS are 
significantly increased when compared to matched historical 
controls. Median OS has been reported between 9.7 to 11.5 
months in GBM. 6PFS for GBM has been reported between 
30%–63%. Median OS and 6PFS in the patients with grade III 
gliomas has been longer than those with grade IV, as would 
be expected. This is a stark improvement when compared to 
6PFS of 21% and OS of 7.5 months (30 weeks).80–83
Retrospective review of tissue from selected study 
participants (AA and GBM) from the time of diagnosis, prior 
to treatment with bevacizumab and irinotecan, in one of the 
phase II trials noted a correlation between specific biomarkers 
and patients responses. VEGF levels in the tumor at time of 
diagnosis correlated with radiographic response, but not over-
all survival. The pretreatment levels of the hypoxia marker, 
hypoxia induced carbonic anhydrase 9 (CA9) corresponded 
to a poor one year survival. The median survival for patients 
with tumors demonstrating high CA9 expression on IHC 
was 37 weeks. Those with low or no CA9 expression had 
a median survival (74 weeks) which was twice as long.85 
A retrospective evaluation of the clinical outcomes of patients 
with recurrent high grade gliomas treated with bevacizumab 
and irinotecan at a single institution demonstrated promis-
ing results. Six month progression-free survival (PFS6) for 
patients with GBM was almost 64% with a median overall 
survival (OS) in these patients of 11.5 months. Over half of 
the patients demonstrated a diffuse pattern of disease spread 
at recurrence.83 Refer to Table 3 for the published trials of 
bevacizumab in glioma. There are numerous ongoing phase II 
clinical trials evaluating the role of bevacizumab in newly 
diagnosed GBM in combination with either temozolomide, 
or irinotecan, during or after RT, The results from these 
studies are still pending. There are also ongoing clinical trials 
using bevacizumab in combination with targeted therapies 
including other anti-angiogenic agents, such as enzastaurin 
(LY317615, Lilly), a serine threonine kinase affecting protein 
kinase C β, in the recurrent setting .
veGF decoy receptors
Aflibercept (VEGF Trap®, Regeneron) is a soluble decoy 
receptor for VEGF-A and placental growth factor (PGF). 
It is composed of the domains of VEGF receptor (VEGFR) 
1 and 2 bound to the constant domain of human immuno-
globulin G1. Recently published studies in mice with glioma 
xenografts reveal an improved overall survival. They also 
demonstrate what appears to represent the development 
of a more invasive diffusely infiltrative phenotype.86 This 
resembles the diffuse pattern of disease recurrence which is 
being seen with bevacizumab and may be found with all anti-
VEGF therapies. Aflibercept is being actively investigated in 
malignant gliomas both at initial diagnosis and recurrence.
Table 3 Clinical trials of bevacizumab in gliomas
Study Additional agents Hisotology Setting Phase
vredenburgh et al80 irinotecan GBM, AA, AOA, AO recurrent ii
vredenburgh et al81 irinotecan GBM recurrent ii
Chen et al76 irinotecan GBM, AA recurrent ii
Lai et al84 Temezolomide GBM Newly diagnosed ii (safety report)
Notes: The paper by Lai and colleagues84 reports the preliminary safety results on the first 10 patients of a larger phase II clinical trial.
Abbreviations: GBM, glioblastoma multiforme; AA, anaplastic astrocytoma; AOA, anaplastic oligoastrocytoma; AO, anaplastic oligodendroglioma. OncoTargets and Therapy 2009:2 125
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veGFr inhibitors
Cediranib (AZD2171, RecentinTM, AstraZeneca) is a small 
molecule tyrosine kinase inhibitor with activity against 
multiple VEGFRs, PDGFa, PDGFb, and c-kit. This “targeted” 
therapy has effects on multiple arms of the angiogenic 
pathway. Correlative studies from a phase II clinical 
trial demonstrate potential biomarkers, which may prove 
important in guiding anti-angiogenic therapy in the future. 
When patients progressed through cediranib there was an 
elevation of serum angiogenic factors bFGF and SDF1a. 
However, when there was evidence of radiographic changes 
to the vasculature during a drug holiday the serum levels 
of those factors did not increase. These findings suggest 
that the timing of dosing of anti-VEGF or VEGFR agents 
may be of significant importance. In this same study of 
patients with recurrent GBM, there was a modest increase 
in OS (211 days vs 175 days) when compared to historical 
controls. A benefit that was also noted was a decrease in 
the vascular permeability which is associated with cerebral 
edema.87 This in turn may help patients decrease their steroid 
requirements and improve their quality of life.
endothelin
Interactions between endothelin-1 (ET-1), ET-2, and ET-3 
with their receptors ETa and ETb are important in normal cell 
growth and proliferation as well as in malignancy. ETa and 
ETb are present in human GBM.88 ET-1 facilitates increased 
VEGF. It also increase HIF-1a expression in normoxic and 
hypoxic states.89
A phase I study through the NABTT of atrasentan (Xinlay®, 
Abbott), an ETa receptor antagonist, used in malignant gliomas 
(almost all recurrent), demonstrated its tolerability. It blocks 
ET-1 induced increases in VEGF. It has also been shown 
to block ET-1 induced activation of HIF-1a. In contrast to 
bevacizumab, where there is a marked decrease in the vascular 
permeability, many of the side effects with atrasentan such as 
edema, rhinorrhea can potentially be attributed to increased 
vascular permeability. In this study there were some partial 
responses as well as stable disease.90 Because of these results, 
a phase II trial with RT/TMZ and atrasentan is planned.
THC
∆9-tetrahydro cannabinoid (THC) has been shown to have 
effects on angiogenesis and tumor growth in mammalian 
xenograft models of gliomas. Its activity is thought to be at 
least in part secondary to its effect on the endogenous can-
nabinoid receptor-1 (CR-1) and/or CR-2. A phase I clinical 
trial in recurrent GBM patients treated with administration 
of intracavitary THC solution administration proved to be 
relatively safe. However, in this study, the investigators were 
not able to demonstrate a significant anti-angiogenic effect 
due to the therapy. As with most clinical trials in gliomas, 
there were a few long term survivors.91
COX-2 pathway
The cyclooxegenase (COX) pathway plays a role in angio-
genesis. Arachidonic acids are converted to prostaglandins 
and thromboxanes via the activity of COX-2. Prostaglandin 
E2 (PGE2) has been shown to induce angiogenesis in animal 
models of cancer. Selective inhibition of COX-2, using cele-
coxib (Celebrex®, Pfizer) has been looked at extensively in a 
number of cancers including gliomas. In preclinical models of 
glioma the effect of celecoxib has been only modest. In turn 
it has been used primarily in combination with other agents 
in the clinical setting without any marked improvement in 
clinical or radiographic parameters.72,92
integrins
The final targeted anti-angiogeneic therapies we will discuss 
are those which target the integrins involved in angiogen-
esis. Integrins are cell surface receptors composed of alpha 
and beta subunits and are involved in binding and signaling 
between cells. There are 24 unique integrin heterodimers. 
Of particular interest as therapeutic targets in many types 
of cancer are αvβ3 and αvβ5 found on endothelial cells as 
well as tumor cells and know to play a role in angiogen-
esis. The integrins, unlike some of the targets mentioned 
previously in this review are not kinases. They are how-
ever involved in activating signaling pathways originating 
from the focal adhesion complexes of which they are a 
component. αvβ3 binds to a number of ligands including 
fibrinogen and fibronectin and is found to be present in both 
tumor angiogenesis and chronic inflammation. Its expres-
sion is stimulated by basic fibroblast growth factor (bFGF). 
Antagonism of αvβ3 induces apoptosis of endothelial cells. 
TGFα and VEGF activate a parallel angiogenic pathway 
involving αvβ5.93
The two above mentioned integrins serve as very reason-
able targets in gliomas. Cilengitide (EMD121974; Merck) 
a αvβ3/αvβ5 antagonist has been evaluated in a number of 
solid tumors including gliomas. Two phase I studies have 
been published evaluating its use in gliomas in the adult 
and pediatric populations and was found to be extremely 
tolerable.94,95 Some of the preclinical data in pancreatic 
cancer demonstrated benefit only with continuous admin-
istration. This may be of importance in the phase II setting. OncoTargets and Therapy 2009:2 126
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Table 4 A selection of ongoing clinical trials in malignant gliomas
Target Agents Phase n ClinicalTrials.gov identifier Histology Newly Dx vs Progression
eGFr Nimotuzimab iii ? NCT00753246 GBM Newly Dx
DNA alkylation Temozolomide
rT
eGFr Cetuximab 
rT
i/ii 46 NCT00311857 GBM Newly Dx
eGFr Nimotuzumab
rT
iii 41 NCT00561691 Diffuse pontine glioma Newly Dx
eGFr Nimotuzumab ii 40 NCT00600054 Diffuse pontine glioma progression
eGFr MAb 425-l125 ii ? NCT00589706 High grade glioma ?
eGFrviii CDX-110 ii 375 NCT00458601 GBM Newly Dx
mTOr Sirolimus i/ii 44 NCT0047073 GBM Progression
mTOr 
eGFr
Sirolimus 
erlotinib
i/ii 99 NCT00509431 Malignant glioma Progression
mTOr 
eGFr
Sirolimus 
erlotinib
ii 20 NCT00672243 GBM Progression
mTOr 
eGFr
Temsirolimus 
erlotinib
i/ii 74 NCT00112736 Malignant glioma Progression
mTOr 
eGFr 
Farnesyl 
transferase
Temsirolimus 
Sorafenib 
erlotinib 
Tipifarnib
i/ii 183 NCT00335764 GBM Progression
mTOr 
DNA alkylation
Temsirolimus 
Temozolomide 
rT
i 56 NCT00316849 GBM Newly Dx
mTOr 
veGF
Temsirolimus 
Bevacizumab
ii ? NCT00800917 GBM Progressive
mTOr 
raf 
veGFr 
PDGFr 
Flt-3 
c-kit 
reT-rTK
Temsirolimus 
Sorafenib
i/ii 141 NCT00329719 GBM Progressive
mTOr 
eGFr
Temsirolimus
erlotinib
i/ii 74 NCT00112736 Malignant glioma Progressive
mTOr 
DNA alkylation
Temsirolimus
Temozolomide
i 15 NCT00784914 Primary and metastatic 
brain tumors
Newly Dx or Progressive
mTOr everolimus i/ii ? NCT00515086 GBM Progressive
mTOr 
veGF 
DNA alkylation
everolimus
Bevacizumab
Temozolomide
rT
ii 60 NCT00805961 GBM Newly Dx
mTOr 
eGFr
everolimus
Gefitinib
i/ii 58 NCT00085566 GBM or Prostate 
cancer
Progressive
mTOr 
DNA alkylation
everolimus
Temozolomide
i 30 NCT00387400 GBM Newly Dx or Progressive
mTOr 
eGFr 
veGFr
everolimus
Ae788
i/ii 113 NCT00107237 GBM Progressive
mTOr 
PDGFr 
c-kit 
Block DNA 
synthesis
everolimus
imatinib
Hydroxyurea
i 72 NCT00613132 GBM Progressive
HDAC 
rAr 
rXr 
DNA alkylation
SAHA
crA
Carboplatin
i/ii 189 NCT00555399 GBM Progressive
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Table 4 (Continued)
Target Agents Phase n ClinicalTrials.gov identifier Histology Newly Dx vs Progression
HDAC 
DNA alkylation
SAHA
Temozolomide
i 77 NCT00268385 Malignant glioma Newly Dx or Progressive
HDAC 
Proteasome
SAHA
Bortezomib
ii 68 NCT00641706 GBM Progressive
HDAC 
veGF 
Topoisomerase i
SAHA
Bevacizumab
irinotecan
i 21 NCT00762255 GBM Progressive
HDAC 
DNA alkylation
SAHA
Temozolomide
i/ii 132 NCT00731731 GBM Newly Dx
HDAC SAHA ii 94 NCT00238303 GBM Progressive
HDAC 
DNA alkylation
valproic acid
Temozolomide
rT
ii 41 NCT00313664 GBM Newly Dx
bFGF 
Topoisomerase i
Lenalidomide
iriontecan
i/ii 51 NCT00671801 GBM Progressive
bFGF Lenalidomide
rT
ii 60 NCT00165477 GBM Newly Dx
bFGF Lenalidomide i 45 NCT00100880 Primary CNS tumors Progressive
veGF 
DNA alkylation
Bevacizumab
Temozolomide
rT
ii 48 NCT00590681 GBM Newly Dx
veGF Bevacizumab ii 35 NCT00337207 GBM Progressive
veGF Bevacizumab
rT
ii 25 NCT00595322 GBM Progressive
veGF
Topoisomerase i
Bevacizumab
irinotecan
ii 167 NCT00345163 GBM Progressive
veGF  
Protein kinase C
Bevacizumab
enzastaurin
ii 80 NCT00559923 Malignant glioma Progressive
veGF 
Protein kinase C
Bevacizumab
enzastaurin
ii 120 NCT00586508 Malignant glioma Progressive
veGF 
eGFr
Bevacizumab
erlotinib
ii 56 NCT00671970 Malignant glioma Progressive
vβ3 
vβ5
Cilengitide i 45 NCT00077155 Lymphoma
Solid tumors
Progressive
vβ3 
vβ5
Cilengitide ii 81 NCT00093964 GBM Progressive
veGF 
PGF
Aflibercept ii 45 NCT00369590 Malignant glioma Progressive
veGF 
PGF 
DNA alkylation
Aflibercept
Temozolomide
rT
i 90 NCT00650923 Malignant glioma Newly Dx or Progressive
p53 Gene therapy i 21–42 NCT00004080 GBM, AA, AOA Progressive
MGMT
DNA alkylation
Gene therapy
Temozolomide
BCNU
O6BG
i 18 NCT00003567 Gliomas, solid tumors, 
NHL
Progressive
MGMT 
microtubules
Gene therapy 
CCNU 
Procarbazine 
vincristine 
O6BG
i 15–20 NCT00729105 CNS tumors Newly Dx or Progressive
Notes: Compiles various active (but not-yet published) clinical trials in malignant gliomas.   All information is available on clinictrials.gov.   The purpose of the table is to serve 
as a reference for the reader interested in the targeted therapies discussed in the paper. it provides the reader with information about what data may be published in the 
near future.
Abbreviations: rT, radiation therapy; GBM, glioblastoma multiforme; AA, anaplastic astrocytoma; AOA, anaplastic oligoastrocytoma; Dx, diagnosis; rTK, receptor tyrosine 
kinase; eGFr, epidermal growth factor receptor; HDAC, histone deacetlyase;  veGF, vascular endothelial growth factor; PGF, placental growth factor; rAr, retinoic acid receptor; 
rXr, retinoid X receptor; MGMT, methylguanine methyl transferase; O6BG, O-6-benzylguanine.OncoTargets and Therapy 2009:2 128
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A recently closed phase I trial which included glioma patients 
used continuous infusion cilengitide; however, the results 
are still pending. A phase II study using bolus scheduling 
of cilengitide was recently completed and is awaiting 
publication.
Neural stem cells
There is growing evidence supporting the role of neural 
stem cells (NSCs) as well as the more differentiated glial 
progenitor cells in gliomagenesis.96 The exact cell(s) of 
origin has(have) not been discovered. NSC have been 
isolated from the subventricular zone and the hippo-
campus in human brains.97,98 NSC and tumor progenitor 
cells bear markers including the glycoprotein CD133, the 
carbohydrate antigen CD15, the transcription factor OLIG2, 
and the intermediate filament protein nestin, distinguish-
ing them from the remaining tumor cell population. The 
resilience of these stem/progenitor cells may underlie the 
refractoriness of tumors to our current therapies such as 
RT.99,100 It is likely that our treatment regimens will need 
to incorporate therapies with activity against both this 
extremely specialized cell population as well as to the 
non-pluripotent cells that compromise the tumors. Some 
of the molecular pathways discussed earlier may remain 
important when targeting glial tumor progenitor cells. For 
example, there is preclinical evidence that EGFR-specific 
TKIs discussed earlier cause cell death in some glioma 
populations exhibiting stem cell markers. It appears intact 
PTEN is essential for this.101 Akt inhibition using small 
molecule kinase inhibitors (SH-6) of cancer stem cells 
leads to decreased cell motility and death. It also leads to 
improved survival in a mouse glioma xenograft model. 
There is also some evidence for decreased cell viability 
with the use of the mTOR inhibitor rapamycin and the 
PI3K inhibitor LY290042.102 Another promising target in 
glioma stem cells, not discussed earlier in this review, is the 
neural cell adhesion molecule L1CAM, which is important 
for cell growth, migration, and survival. CD133+ glioma 
cells are enriched for L1CAM. Use of lentivirus shRNA 
targeting L1CAM has demonstrated growth inhibition in 
cellular models and improved survival in mouse glioma 
xenograft models.103 There is very active preclinical work 
investigating the targeting of glioma stem cells. The bulk 
of clinical trial activity using stem cells however is not as 
a therapeutic target, but in their use as a rescue after high-
dose chemotherapy.
There is also active ongoing work in the use of NSCs 
as delivery mechanisms for other targeted therapies. 
It has been demonstrated that NSCs and bone marrow 
derived mesenchymal stem cells (MSC) home in on glial 
MRI T1 post-Gadolinium image August 14, 2007 MRI T1 post-Gadolinium image September 5, 2007
Figure 5 Mri scans showing a typical response of a recurrent GBM to bevacizumab. The image on the right shows the tumor-associated enhancement (large arrow) and 
accompanying compression of the ventricle by mass effect (small arrow). The image on the right shows the same region following a one month course of bevacizumab. Note 
the marked reduction in contrast enhancement and mass effect.
Abbreviations: GBM, glioblastoma multiforme; Mri, magnetic resonance imaging.OncoTargets and Therapy 2009:2 129
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tumor cells in animal models.104 This may prove to be 
an efficacious vehicle for administering and adequately 
distributing a targeted therapy to tumor cells. NSCs 
and MSCs have been used to deliver via viral vectors a 
number of genes including interleukins, INFβ, as well as 
genes effecting the extracellular matrix, apoptosis, and 
pro-drug activating enzymes.105 NSCs appear to have a 
tropism towards the necrotic center as well as invading 
edge of glioma xenografts.106 There is concern that many 
therapies do not reach adequate concentrations in regions 
of necrosis within the tumor, and using stem cells may 
be a means to circumvent this. Although the xenograft 
model does not accurately represent the invasive nature of 
gliomas in humans, the tumor cells which are most actively 
invading the surrounding parenchyma are an important 
target. It has recently been shown that NSCs and MSCs 
can deliver oncolytic adenoviruses to tumor cells with 
good distribution throughout the tumor, and not relying 
on passive diffusion of the adenoviruses.107,108
Gene therapy
The final means of addressing specific targets in gliomas 
which we will touch on is gene therapy. Gene therapy 
is a means for either replacing defective or silent tumor 
suppressor genes in tumors or of adding in new genes 
which may serve an oncolytic purpose. While we will 
only address this subject briefly, further reading can be 
found in a recent review.109 Components of the molecular 
pathways such as p53 or PTEN, could serve as a potential 
way to reverse the malignant phenotype and potentially 
make the tumor cells more susceptible to other specific 
therapies. Transduction of p53 has been explored in clini-
cal trials, however, many of the tumor cells further from 
the administration site of the vector did not take up the 
virus and express p53.110 Efforts are also ongoing using the 
insertion of methylguanine methyl transferase (MGMT) 
into hematopoetic cells in conjunction with traditional 
chemotherapies in combination with O-6-benzylguanine 
(O6BG). The majority of more recent scientific effort, 
however, has been to introduce genes into the tumor 
that would lead to cell death. Viral thymidine kinase 
enzyme, which is targeted by the antivirals acyclovir 
(Zovirax®; GlaxoSmithKline, Philadelphia, PA), has 
been incorporated into the tumor cells DNA. Treatment 
with the antiviral agents leads to DNA chain termination, 
potentially leading to cell death.111,112 Various cytokines 
including IFNβ, interleukin 2 (IL-2), IL-4, IL-12, as well 
as others are being evaluated.113–116
Viral vectors have been used as the primary means 
of introducing genes into tumor cells. Nonreplicating or 
conditionally replicating adenoviruses and herpes viruses 
have been primarily used. One of the limitations of delivery 
of genes via viral vectors has been an inability to infect all 
tumor cells. As discussed above, NSCs are being used to 
circumvent this problem. There are currently clinical trials, 
both ongoing as well as in development, using gene therapy 
to treat malignant gliomas.
Gene therapy continues to hold significant promise 
in the treatment of cancers, including malignant glio-
mas. Tremendous efforts have been made to overcome the 
various obstacles which impede the efficacy of this treatment 
modality.
Conclusion
We have reviewed the experience to date with targeted 
therapies in the treatment of malignant gliomas. The data 
presented reflect years of work by basic scientists, pharma-
cologists, and clinical investigators. Many human subjects 
have participated in studies. In reviewing the clinical out-
comes, readers may reach the conclusion that little impact 
has been made on malignant gliomas to date. This may 
hold for these tumors as a whole. However, the impressive 
responses seen in subsets of patients following treatment with 
either single-agent tyrosine kinase inhibitors or EGFRvIII 
vaccines speak to the potential of this approach. Given these 
findings, it is tempting to ponder the relevance of increas-
ingly personalized medicine as the molecular heterogene-
ity of these tumors is well documented. Alternatively, the 
promising results emerging in the majority of patients treated 
with anti-VEGF antibodies upon tumor progression argues 
in favor of the continued search for an “Achilles’ heel.” 
Ultimately, these approaches are not mutually exclusive 
and offer new hope for people suffering the consequences 
of malignant glioma. Future directions include combinations 
of various targeted agents, either with one another or with 
more conventional chemotherapies and/or radiotherapy. 
These studies are underway. In addition, new agents, as yet 
untested, are in active development. Thus, after decades of 
limited progress in advancing the treatment of malignant 
gliomas, breakthroughs are occurring co-incident with the 
development of rationally targeted agents derived from an 
improved understanding of cancer biology.
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